Nathan Dowden Biography and Net Worth

Nate was previously Senior Vice President for Corporate Development at Rubius Therapeutics and prior to that he was in Managing Director roles at the Huron Consulting Group and The Frankel Group LLC advising biotechnology, biopharmaceutical, diagnostic and medical device companies. Nate also worked at Ernst & Young advising hospital systems and managed care companies, and at Searle Pharmaceuticals (now part of Pfizer), and CIGNA Healthcare.

Nate holds an MBA from the Booth School of Business at the University of Chicago and a BS from the University of Connecticut.

What is Nathan J. Dowden's net worth?

The estimated net worth of Nathan J. Dowden is at least $1.27 million as of September 26th, 2024. Mr. Dowden owns 125,149 shares of Entrada Therapeutics stock worth more than $1,271,514 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Dowden may own. Additionally, Mr. Dowden receives a salary of $694,300.00 as President and Chief Operating Officer at Entrada Therapeutics. Learn More about Nathan J. Dowden's net worth.

How old is Nathan J. Dowden?

Mr. Dowden is currently 53 years old. There are 3 older executives and no younger executives at Entrada Therapeutics. The oldest executive at Entrada Therapeutics is Dr. Natarajan Sethuraman Ph.D., Chief Scientific Officer, who is 62 years old. Learn More on Nathan J. Dowden's age.

What is Nathan J. Dowden's salary?

As the President and Chief Operating Officer of Entrada Therapeutics, Inc., Mr. Dowden earns $694,300.00 per year. The highest earning executive at Entrada Therapeutics is Mr. Dipal Doshi, CEO & Director, who commands a salary of $968,210.00 per year. Learn More on Nathan J. Dowden's salary.

How do I contact Nathan J. Dowden?

The corporate mailing address for Mr. Dowden and other Entrada Therapeutics executives is , , . Entrada Therapeutics can also be reached via phone at 857-520-9158 and via email at [email protected]. Learn More on Nathan J. Dowden's contact information.

Has Nathan J. Dowden been buying or selling shares of Entrada Therapeutics?

Nathan J. Dowden has not been actively trading shares of Entrada Therapeutics during the past quarter. Most recently, Nathan J. Dowden sold 847 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $16.00, for a transaction totalling $13,552.00. Following the completion of the sale, the chief operating officer now directly owns 125,149 shares of the company's stock, valued at $2,002,384. Learn More on Nathan J. Dowden's trading history.

Who are Entrada Therapeutics' active insiders?

Entrada Therapeutics' insider roster includes John Crowley (Director), Dipal Doshi (CEO), Nathan Dowden (President and Chief Operating Officer), Kush Parmar (Director), Natarajan Sethuraman (Insider), and Kory Wentworth (CFO). Learn More on Entrada Therapeutics' active insiders.

Are insiders buying or selling shares of Entrada Therapeutics?

In the last twelve months, Entrada Therapeutics insiders bought shares 3 times. They purchased a total of 178,044 shares worth more than $1,352,567.90. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 685,845 shares worth more than $5,867,281.75. The most recent insider tranaction occured on November, 21st when CFO Kory James Wentworth sold 8,910 shares worth more than $88,921.80. Insiders at Entrada Therapeutics own 8.1% of the company. Learn More about insider trades at Entrada Therapeutics.

Information on this page was last updated on 11/21/2025.